Pharmanutra PR - First Sales on the US Market Stock: price and insider trades · Italy
Pharmanutra PR - First Sales on the US Market: what insiders have been doing
Insider filings for Pharmanutra PR - First Sales on the US Market are scarce in the Consob feed, the latest one published on 3 October 2023. This page will fill in as new trades are disclosed. These figures are compiled from regulatory filings published by Consob. They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 8,002 of 26,911 companies
61.7
score / 100
Value38
Quality85
FCF yld2.1%
Earn yld2.6%
EV/EBITDA23.5x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€81.90
Analyst consensus
3 analysts1.00/5
€76.00Target €81.33(-1%)€86.00
Income statement
Revenue€132.9M
Gross profit€102.9M77% margin
EBITDA€34.3M26% margin
Net income€20.0M15.1% margin
Valuation
PER (trailing)37.2x
PER (forward)26.7x
P/Book10.6x
Beta0.17
Balance sheet & cash
Market cap€784.2M
Total debt€20.5M
Free Cash Flow€16.4M
Debt / Equity26%
Profitability & ownership
ROE30.1%
ROA15.2%
% insiders65.0%
% institutions17.2%
Last declaration on 3 October 2023
Declarations1 total
- ●Executives0Consob
1 of 1 declaration
About Pharmanutra PR - First Sales on the US Market
Pharmanutra PR has made its first sales in the US market, marking an important milestone in its international expansion. The company specializes in the development of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
